A Validated Tool Can Predict Risk of Developing Thyroid Eye Disease During Antithyroid Drug Treatment of Graves’ Disease | oneGRAVESvoice
Global Search
Global Search

Trusted Resources: Evidence & Education

Scientific literature and patient education texts

Back to Evidence & Education / Patient Education

A Validated Tool Can Predict Risk of Developing Thyroid Eye Disease During Antithyroid Drug Treatment of Graves’ Disease

key information

source: Clinical Thyroidology

year: 2018

summary/abstract:

Over-activity of the thyroid gland, called hyperthyroidism, can sometimes be caused by a flaw in a person’s immune system (the body’s natural defense system against infection). This problem is a type of autoimmune disorder called Graves’ disease. In addition to thyroid gland over-activity, Graves’ disease causes eye problems in some people, including eye bulging, loss of color vision, double vision, eye pain and dry eyes.

Not everyone diagnosed with Graves’ disease will develop eye problems. Identifying people diagnosed with Graves’ disease who do develop eye disease is important, however, because early treatment may make these eye problems less severe. The goal of this study is to identify which people diagnosed with Graves’ disease will eventually have eye problems. Such people could then be treated for these eye problems before these problems become severe, and possibly irreversible.

 

read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Powered by

Brought to you by

Supported through an independent
educational grant by

© 2022 rareLife solutions Inc.